Using Targeted Therapies for T Cell Lymphoma Transplant Patients
Jasmine Zain, MD, discusses how her institution is working on improving the outcome of patients with T cell lymphoma that undergo transplants.
Jasmine Zain, MD, from the Center for the Lymphoid Malignancies, Columbia University Medical Center, discusses how her institution is working on improving the outcome of patients with T cell lymphoma that undergo transplants.
Clinical Pearls:
- Columbia’s new transplant program is working on moving targeted therapies into the transplant setting
- Columbia’s transplant program is hoping to develop protocols for transplantation that will include targeted therapies such as pralatrexate, romidepsin, and ibrutinib as maintenance therapy to reduce toxicity
- This will ultimately improve the outcome for these patients
Recent Videos
Related Content
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022Podcast
In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
